1/ Vifor Pharma licenses rights to commercialise ChemoCentryx’s orally-administered complement 5aR inhibitor CCX168 for orphan and rare renal diseases in Europe and certain other major markets. 2/ FY15 profit jumped 18.6%, including only 5.8% for Galenica.
11 May 2016
Vifor Pharma licenses marketing rights to CCX168 in certain territories
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Vifor Pharma licenses marketing rights to CCX168 in certain territories
Galenica AG (0ROG:LON) | 0 0 0.0% | Mkt Cap: 2,446m
- Published:
11 May 2016 -
Author:
Armelle Moulin -
Pages:
3
1/ Vifor Pharma licenses rights to commercialise ChemoCentryx’s orally-administered complement 5aR inhibitor CCX168 for orphan and rare renal diseases in Europe and certain other major markets. 2/ FY15 profit jumped 18.6%, including only 5.8% for Galenica.